Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Equity Average (2018 - 2025)

Cue Biopharma's Equity Average history spans 8 years, with the latest figure at $15.7 million for Q3 2025.

  • For Q3 2025, Equity Average fell 33.16% year-over-year to $15.7 million; the TTM value through Sep 2025 reached $15.7 million, down 33.16%, while the annual FY2024 figure was $27.3 million, 46.89% down from the prior year.
  • Equity Average for Q3 2025 was $15.7 million at Cue Biopharma, up from $12.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $74.3 million in Q1 2021 and bottomed at $12.0 million in Q1 2025.
  • The 5-year median for Equity Average is $50.5 million (2023), against an average of $45.2 million.
  • The largest annual shift saw Equity Average soared 48.85% in 2021 before it plummeted 64.13% in 2025.
  • A 5-year view of Equity Average shows it stood at $64.5 million in 2021, then fell by 9.74% to $58.2 million in 2022, then tumbled by 31.51% to $39.9 million in 2023, then crashed by 46.25% to $21.4 million in 2024, then dropped by 26.74% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Equity Average are $15.7 million (Q3 2025), $12.4 million (Q2 2025), and $12.0 million (Q1 2025).